Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | BGB-26808 + Tislelizumab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BGB-26808 | BGB26808|BGB 26808 | MAP4K1 Inhibitor 7 | Limited information is currently available on BGB-26808, a putative MAP4K1 (HPK1) Inhibitor (Sep 2023). | |
Tislelizumab | BGB-A317 | Immune Checkpoint Inhibitor 147 PD-L1/PD-1 antibody 117 | Tislelizumab (BGB-A317) is a human monoclonal antibody that targets PD-1 (PDCD1), thereby blocking the binding of PD-L1 (CD274) and potentially resulting in activation of a T-cell immune response against tumor cells (PMID: 32769013, PMID: 32561638, PMID: 32540858). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05981703 | Phase I | BGB-26808 + Tislelizumab | A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors | Recruiting | USA | NZL | AUS | 1 |